Literature DB >> 3530255

Detection of native and denatured DNA antibody forming cells by the enzyme-linked immunospot assay. A clinical study of (New Zealand black x New Zealand white)F1 mice.

D G Ando, F M Ebling, B H Hahn.   

Abstract

A new method for measuring DNA antibody forming cells (DNA-AFC) using the enzyme-linked immunospot (ELISPOT) assay is described. This method uses enzyme-linked immunosorbent assay (ELISA) techniques applied to cells cultured on DNA-coated plates, which allows visual quantitation of spots representing imprints of specific antibodies from DNA-AFC. Specificity for DNA was confirmed by inhibition studies and lack of reactivity by anti-lysozyme hybridomas. Isotypes of IgG and IgM can be measured using the appropriate antisera in the assay. A study of 16 female (New Zealand black x New Zealand white)F1 ([NZB x NZW]F1) female mice showed significant correlation between age, rising blood urea nitrogen levels, and increasing proteinuria and increasing numbers of DNA-AFC. In contrast, the correlation between circulating antibodies to DNA (ELISA method) and clinical parameters of nephritis was not significant. Both the native DNA ELISPOT and the native DNA ELISA had similar significant linear correlations with age. This is the first report of use of the ELISPOT assay for measurement of DNA-AFC. The DNA-AFC measured by this method were specific and correlated with the presence of clinical nephritis in (NZB x NZW)F1 mice. This method should allow further study on the regulation of DNA-AFC in vitro and in vivo, and will be useful in the investigation of DNA-AFC and cellular mechanisms of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530255     DOI: 10.1002/art.1780290912

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

1.  Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus.

Authors:  N Suzuki; T Sakane; E G Engleman
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

2.  Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease.

Authors:  D M Klinman
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

3.  Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

Authors:  N Harata; T Sasaki; H Osaki; T Saito; S Shibata; T Muryoi; O Takai; K Yoshinaga
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

4.  Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate.

Authors:  M Blank; J Manosroi; Y Tomer; A Manosroi; J Kopolovic; S Charcon-Polak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

5.  Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation.

Authors:  A Shirai; M Cosentino; S F Leitman-Klinman; D M Klinman
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

6.  Induction of tolerance to an IgG autoantibody.

Authors:  D Offen; L Spatz; H Escowitz; S Factor; B Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

7.  Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus.

Authors:  R R Singh; B H Hahn; B P Tsao; F M Ebling
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

8.  The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms.

Authors:  K Takeda; G Dennert
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

9.  Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells.

Authors:  D M Klinman; K W Higgins; J Conover
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

10.  Systemic autoimmune disease arises from polyclonal B cell activation.

Authors:  D M Klinman; A D Steinberg
Journal:  J Exp Med       Date:  1987-06-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.